The production of recombinant proteins has transformed the field of biomedical biotechnology. The advent of recombinant DNA technology, which is experiencing developments for the past four decades, has resulted in the recombinant therapeutic proteins as novel and useful drugs for different kind of human diseases. Consequently, the recombinant protein market is overgrowing with its rising applications in therapeutic applications, treatments, and drugs. Compared to conventional drugs, recombinant proteins achieve greater efficacy, offer higher safety, and cover a broader range of illnesses which can effectively cure different types of diseases such as infectious diseases, cancers, metabolic deficiencies, and autoimmune disorders. However, the production and development of these recombinant proteins play a significant role to achieve the required production yield and quality of the end product. Different strategies and approaches are employed for the optimization of these recombinant proteins. Therefore, the experiments pertaining to the recombinant protein expression systems are advancing rapidly in the recombinant protein market.

Furthermore, these activities on expression systems are gaining massive traction in the Recombinant Protein Market. As a result, the recombinant protein market size attained a global value of $350m in 2018. Furthermore, the market is projected to thrive at a CAGR of 6%, during the forecast period 2019-2025.

Advancements in the Expression Systems Are Gaining Prominence in the Recombinant Protein Market

Significance of the expression system in recombinant protein is stupendous, and the selection depends on production costs, physicochemical and economic properties of the target protein, and the desired application. Based on these selection criteria, insect, bacterial, yeast, and mammalian expression systems are widely in use. Besides, the research activities of the cell-free expression systems are increasing rapidly. For instance, a new study by Northwestern University found that there is a scope for better quality in the production of protein therapeutics and biomaterials. The team has developed a new bacterial cell-free protein synthesis system, which has the competency of producing high quality proteins that contain multiple non-canonical amino acids. This research activity could allow the decentralization of manufacturing process and proficient distribution for protein therapeutics, which foresees a better future for easy access to the costly drugs around the world. Besides the drug delivery systems, the team foreknows the scope of applications in medical materials such as functionalized biopolymers. It has the potential to enable a paradigm of on-demand bio-manufacturing of therapeutics and vaccines. This kind of research activities in the expression systems is rapidly rising in the recombinant protein market.

North America’s Robust Research Base to Boost the Recombinant Protein Market Growth

Since its inception in the 1980s, recombinant protein production is significantly rising in the pharmaceutical industry. Pharmaceutical advancements have proficiency in reducing the costs incurred by healthcare providers and governments of countries. Systems and technologies to produce target proteins and their variants are evolving continuously in this sector. In the pharmaceutical industry, many recombinant protein projects targeting the extraction, analysis, and purification of protein targets from animal tissue are the areas experiencing further advancements. New technological advancements are continuously evolving to improve microorganism production of biopharmaceuticals. These research activities are of huge prominence in the United States. The U.S. held a dominant share of 40.3% in the global pharmaceutical market as of 2015, and the share will increase to a value of 41% by 2020. In this country, there is a paradigm shift of collaboration between R&D and pharmaceutical industries that are boosting the demand for the recombinant protein market. Furthermore, this trend is enabling the industries and healthcare partners to work towards common goals and mitigate the innovation costs, increase flexibility, and efficiency. As a result, the research-based pharmaceutical industry of the U.S is thriving with R&D of new medicines and vaccines to improve the patient’s life, which are evident in the technological innovations of recombinant protein expression. On the whole, the robust healthcare sector of Canada and research activities of the U.S. makes North America recombinant protein market to find broad opportunities further. Subsequently, the region accounted for a share of 43% in the global recombinant protein market in 2018. 

Advantages of Research Institutes Influence the Recombinant Protein Market Demand

To turn research activities to commercial reality, the researchers need the support of research institutes to achieve potentially valuable proteins. Without support from the research institutes, researchers often face critical challenges in the production of recombinant proteins. These challenges are in the form of animal preclinical and human clinical trials. Besides, these institutes also assist with optimization, scale-up, and purification of recombinant proteins in larger quantities.

Furthermore, this large scale production can be carried out using sophisticated fermentation equipment. The major research institutes can offer the flexibility of collaborating with industries and academic institutes for the development of various recombinant protein expression systems. Owing to all these benefits offered, the research institutes end-use industry of the global recombinant protein market demand is rising at a CAGR of 5.5%, during the period mentioned above. Also, the commercial protein products thus obtained can be utilized in the development of drugs, nutraceuticals, therapeutic purposes, and industrial enzymes which have commercial significance.

Dominant Players in the Recombinant Protein Market

The key players in the recombinant protein industry are Enzo Biochem, Inc., Thermo Fisher Scientific, Abcam plc, Bio-Techne, Bio-Rad Laboratories, and others. Recent developments such as expansions, acquisitions, new product launches, and partnerships are increasing the revenue of these significant stakeholders of the recombinant protein industry.

Few of the latest acquisitions by the major players of this industry include:

· In 2019, Thermo Fisher Scientific acquired Brammer Bio, which specializes in the viral vector manufacturing of cell and gene therapy. Thermo Fisher Scientific adds the latest acquisition to its pharma services businesses to enhance the assistance by enabling gene therapy to their pharmaceutical and biotech customers. Furthermore, the company mentioned that with the opportunities thriving in the market, there would be a robust pipeline of gene therapy developments that can be experienced in the near future. 

· In 2019, Abcam plc, a global leader in life science reagents and tools has acquired Calico Biolabs, a developer of custom high-quality recombinant rabbit monoclonal antibodies that offer services to diagnostics and pharmaceutical companies. With this acquisition, Abcam plc expands as a leader in recombinant rabbit monoclonal antibody technology. It further provides access to the best antibodies for its customers.

Talk to one of our sales representative about the full report by providing your details in the link below:

Related Reports:

A. Protein Expression Market

B. Protein Drugs Market


Any other custom requirements can be discussed with our team, drop an e-mail to [email protected] to discuss more about our consulting services.

To request for a quote, provide your details in the below link:


Media Contact:

Mr. Venkat Reddy

Sales Manager          

Email: [email protected]

Contact Sales: +1-614-588-8538 (Ext-101)

About IndustryARC: IndustryARC is a research and consulting firm that publishes more than 500 reports annually, in various industries such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food and Beverages, Information Technology, and Life sciences and Healthcare.